Literature DB >> 2613917

Detection of erythroid hypoplasia in myelofibrosis using erythrokinetic studies.

J E Howarth1, H M Waters, K Hyde, C G Geary.   

Abstract

The iron kinetic model described by Ricketts et al was used to study haemopoiesis in chronic myelofibrosis. The clearance of 59Fe-labelled transferrin from the plasma was analysed to quantify total, effective, and ineffective erythropoiesis, denoted by the terms marrow iron turnover (MIT), red cell iron turnover (RCIT), and per cent ineffective iron turnover (IIT%), respectively, in 12 cases of this disease. The patterns obtained were variable: values for MIT ranged from 24.4 to 510 mumol/l blood/day; those for RCIT from 0.4 to 119 mumol/l blood/day; and those for IIT% from 67 to 98%. One noteworthy feature was the presence in two cases of functional erythroid hypoplasia; these were characterised by severely reduced values for MIT (24.4 and 28 mumol/l blood/day) and RCIT (0.4 and 8 mumol/l blood/day.) A systematic study of the erythrokinetic features of myelofibrosis may indicate that erythroid hypoplasia is a more common cause of anaemia in this disease than has been previously recognised.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2613917      PMCID: PMC502048          DOI: 10.1136/jcp.42.12.1250

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell lifespan using 59Fe.

Authors:  C Ricketts; A Jacobs; I Cavill
Journal:  Br J Haematol       Date:  1975-09       Impact factor: 6.998

2.  Erythroid hypoplasia in myelofibrosis: a feature associated with blastic transformation.

Authors:  S A Bentley; K H Murray; S M Lewis; P D Roberts
Journal:  Br J Haematol       Date:  1977-05       Impact factor: 6.998

3.  The measurement of 59Fe clearance from the plasma.

Authors:  I Cavill; C Ricketts; J A Napier; A Jacobs; D Trevett; R D Bishop
Journal:  Scand J Haematol       Date:  1976-09

4.  The influence of regional haematocrit on "in vivo" ferrokinetic measurements.

Authors:  G Barosi; A Baraldi; A Berzuini; L Mascaretti; P Palestra; G Polino; S Ramella; F Rossi; P Spriano; I Cavill
Journal:  Haematologica       Date:  1984 Jul-Aug       Impact factor: 9.941

5.  Anaemia in myelofibrosis: its value in prognosis.

Authors:  O S Njoku; S M Lewis; D Catovsky; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

6.  Red cell hypoplasia, thrombocytosis, and leucocytosis: myelodysplastic and proliferative syndrome.

Authors:  A Craig; C G Geary; E M Love; J Liu-Yin
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

7.  A prognostic classification of myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; C Berzuini; L N Liberato; A Costa; G Polino; E Ascari
Journal:  Br J Haematol       Date:  1988-12       Impact factor: 6.998

8.  Red cell aplasia and chronic granulocytic leukaemia.

Authors:  E N Dessypris; C L McKee; C Metzantonakis; M Teliacos; S B Krantz
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

9.  Transitional myeloproliferative disorder.

Authors:  J E Pettit; S M Lewis; A W Nicholas
Journal:  Br J Haematol       Date:  1979-10       Impact factor: 6.998

10.  Erythropoiesis in myelofibrosis with myeloid metaplasia: recognition of different classes of patients by erythrokinetics.

Authors:  G Barosi; M Cazzola; F Frassoni; E Orlandi; M Stefanelli
Journal:  Br J Haematol       Date:  1981-06       Impact factor: 6.998

  10 in total
  1 in total

1.  Comparative ferrokinetic study with initial and extended iron clearance models.

Authors:  J E Howarth; H M Waters; K Hyde; D Shanks; C G Geary
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.